Can a blood pressure drug reverse heart scarring after aortic repair?

NCT ID NCT06150560

ENROLLING_BY_INVITATION Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial tests whether losartan, a common blood pressure medication, can reduce scarring in the heart's main pumping chamber and improve exercise capacity in adults who had surgery to repair coarctation of the aorta. Participants will take losartan, amlodipine, or a placebo daily for a year. The study uses MRI scans and exercise tests to measure changes in heart tissue and fitness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Losartan (an angiotensin-II receptor blocker, also known as Cozaar), compared against amlodipine and placebo
What this could lead to
If successful, losartan could become a standard treatment to reduce heart muscle scarring and improve exercise tolerance in people who had coarctation repair, potentially lowering long-term cardiovascular risks.
What could go wrong
This is a phase 3 trial, but results are not yet known. The drug may not outperform amlodipine or placebo, and side effects like dizziness, high potassium, or kidney issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COARCTATION OF AORTA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.